Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Sectors

Investors bow to Sensei series A

Cambrian Biopharma co-led a $28.5m round for cancer immunotherapy developer Sensei Biotherapeutics with venture capital firm H&S Ventures.


Oct 10, 2020

Doherty and Delph take Magic Leap roles

John Doherty, a GCV Powerlist award winner, becomes CFO as Walter Delph heads business.

Oct 10, 2020

Corporate venturing deal net: 5-9 October 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Oct 9, 2020

Daily deal net: October 9, 2020

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Oct 9, 2020

UPMC crosses Abridge for $15m

Medical transcription technology provider Abridge has emerged from stealth with seed and series A funding.

Oct 9, 2020

Gamma Biosciences absorbs Nanopareil

Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

Oct 9, 2020

Big Hit braces for $842m IPO

Big Hit Entertainment, the Netmarble-backed talent management agency and record company, priced its initial public offering at the top of its range.

Oct 9, 2020

Will Ventures locks down $50m fund

University endowment-backed Will Ventures aims to unlock sports-related innovation across markets such as fitness, media and gaming.

Oct 9, 2020

A2 coordinates $71.5m series B

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Oct 9, 2020

GoPuff gets $380m in SoftBank-backed round

Returning investor SoftBank Vision Fund came back for a round that valued the consumer product delivery platform at $3.9bn.

Oct 9, 2020

Instacart picks up another $200m

The Comcast, American Express and Amazon-backed grocery delivery service increased its valuation to $17.7bn in a round co-led by Valiant Peregrine Fund and D1 Capital Partners.

Oct 9, 2020

A2 coordinates series B round

Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

Oct 9, 2020
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here